Molecular Partners AG (MOLN) has a negative trailing P/E of -2.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 41.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -50.59%, forward earnings yield 2.44%.
Criteria proven by this page:
Overall SharesGrow Score: 50/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -21.9 | 0.00 | 3.01 | 17.73 | - |
| 2017 | -15.7 | -0.46 | 3.42 | 19.94 | - |
| 2018 | -11.0 | -0.25 | 4.46 | 39.52 | - |
| 2019 | -11.2 | 3.27 | 7.52 | 19.96 | - |
| 2020 | -6.9 | -0.14 | 4.06 | 46.56 | - |
| 2021 | -8.5 | 0.47 | 5.05 | 58.11 | - |
| 2022 | 1.7 | -0.01 | 0.84 | 1.04 | - |
| 2023 | -1.9 | 0.01 | 0.65 | 16.36 | - |
| 2024 | -2.7 | 0.17 | 1.04 | 29.53 | - |
| 2025 | -2.1 | -0.55 | 1.60 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.91 | $23.04M | $-18.61M | -80.8% |
| 2017 | $-1.22 | $20.02M | $-25.43M | -127% |
| 2018 | $-1.75 | $10.36M | $-37.04M | -357.7% |
| 2019 | $-1.69 | $20.38M | $-36.29M | -178% |
| 2020 | $-2.51 | $9.34M | $-62.76M | -671.7% |
| 2021 | $-2.06 | $9.33M | $-63.79M | -683.7% |
| 2022 | $3.54 | $189.56M | $117.85M | 62.2% |
| 2023 | $-1.89 | $7.04M | $-61.98M | -880.7% |
| 2024 | $-1.59 | $4.97M | $-54.04M | -1087.4% |
| 2025 | $-1.65 | $0.00 | $-61.65M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.27 | $-1.61 – $-0.69 | $5.53M | $5.53M – $5.53M | 3 |
| 2027 | $-0.93 | $-3.02 – $4.02 | $30.9M | $30.9M – $30.9M | 3 |
| 2028 | $-1.43 | $-1.62 – $-1.24 | $1.25M | $1.25M – $1.25M | 2 |
| 2029 | $-1.47 | $-1.47 – $-1.47 | $33.69M | $33.69M – $33.69M | 1 |
| 2030 | $0.10 | $0.10 – $0.10 | $179.95M | $179.95M – $179.95M | 1 |
